The CBP/p300 HAT inhibitor C646 sensitizes non-small cell lung cancer cells to radiotherapy by abrogating checkpoint maintenance and augmenting radiotherapy-induced mitotic catastrophe 105. Here, EP300 is linked to non-small cell lung carcinoma.